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Abstract
Background: Hsp90 is an essential molecular chaperone that is also a novel anti-cancer drug target. There is growing
interest in developing new drugs that modulate Hsp90 activity.
Methodology/Principal Findings: Using a virtual screening approach, 4-hydroxytamoxifen, the active metabolite of the
anti-estrogen drug tamoxifen, was identified as a putative Hsp90 ligand. Surprisingly, while all drugs targeting Hsp90 inhibit
the chaperone ATPase activity, it was found experimentally that 4-hydroxytamoxifen and tamoxifen enhance rather than
inhibit Hsp90 ATPase.
Conclusions/Significance: Hence, tamoxifen and its metabolite are the first members of a new pharmacological class of
Hsp90 activators.
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Introduction
Hsp90 is a ubiquitous ATP-dependent dimeric molecular
chaperone that plays a central role in cellular signalling pathways
since it is essential for maintaining the activity of several signalling
proteins including steroid hormone receptors and protein kinases.
In eukaryotes, cytoplasmic Hsp90 is absolutely essential for cell
viability under all growth conditions [1,2]. Hsp90s typically
function as part of large complexes that include other chaperones
and essential cofactors regulating Hsp90 function. It is thought
that different cofactors target Hsp90 to different sets of substrates.
However, the mechanism of Hsp90 function remains poorly
understood.
The broad effect of Hsp90 on protein cellular homeostasis arises
from the large number of client substrates that this chaperone acts
upon. For example, we recently demonstrated that about 10% of
the yeast proteome genetically or physically interacts with Hsp90
[3]. In mammalian cells, more than one hundred Hsp90 substrates
have been identified including a large number of transcription
factors and protein kinases such as glucocorticoid receptor, p53
mutant, vSrc, Hck, CFTR, and many others [4].
Hsp90 is currently a novel anti-cancer drug target [5,6]. The
inhibition of Hsp90 activity typically results in the degradation of
Hsp90 client substrates and, consequently, in the blocking of
multiple cellular pathways [7]. This seems to affect tumour
progression [8]. Several Hsp90 inhibitors have been identified
from natural products and some have also been chemically
synthesized. For example, fungal antibiotics belonging to the
benzoquinone ansamycin family, such as geldanamycin, herbimy-
cin A, and macbecin, were found to specifically bind to Hsp90. It
has been shown that geldanamycin directly binds to the ATP-
binding pocket in the N-terminal domain of Hsp90 [9,10] and
blocks the binding of nucleotides to Hsp90. A geldanamycin
derivative, 17-(allylamino)-17-demethoxygeldanamycin (17-AAG),
is now progressing to phase II clinical trials [11,12,13,14]. Other
natural product Hsp90 inhibitors include the macrolide radicicol
and its derivatives [15]. Synthetic small-molecule inhibitors of
Hsp90 have also been designed based on the available X-ray
structures of the chaperone. One such class of Hsp90 inhibitors are
the purine scaffold derivatives (such as PU3) [16], while another
such synthetic inhibitors are the pyrazole resorcinols [17].
Hence, there is growing interest in developing new drugs that
modulate Hsp90 activity. While Hsp90 inhibition has been clearly
established as a valid entry point for clinical intervention in
oncology, the therapeutic relevance of Hsp90 activation in other
disease areas remains unexplored. In this study, we report the
unexpected identification of small molecule activators of Hsp90.
Such activators of Hsp90 ATPase have not been described before
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Materials and Methods
Docking Procedure
A library of 4403 pockets co-crystallized with ligands of
molecular weight between 100 to 500 Da having a volume larger
than 200 A ˚ 3 and a resolution better than 2.5 A ˚ was extracted from
the Protein Data Bank (PDB) using the IcmPocketFinder macro of
the ICM computational chemistry platform (Molsoft LLC, CA), as
described elsewhere [18]. The library contained 16 Hsp90 pockets
and 29 pockets from other chaperones (Table S1). Each site was
automatically reformatted into a dock-ready grid potential that
accounts for van der Waals shape, hydrophobicity profile, and
hydrogen-bond network. The flexible ligand was docked with
ICM to each grid by a Monte Carlo energy minimization in the
internal coordinates space and assigned a score based on the
quality of the fit, including the entropy of the system and Poisson
electrostatics [19]. ICM docking thoroughness was set to 1 and
default virtual screening parameters of version 3.6-1d of the
software were used. The simulation takes on average 45 seconds
per receptor per CPU.
Protein Expression and Purification
Escherichia coli ClpX [20] and human Hsp70 [21] were purified
as previously described. Saccharomyces cerevisiae (yeast) Hsp82,
different domains of yeast Hsp82, and human Hsp90a were
expressed in E. coli strain BL21-CodonPlus (DE3)-RIL (Stratagene)
from plasmid pProEX HTa with a His6-tag followed by a tobacco
etch virus (TEV) protease cleavage site fused at the N-terminus of
the protein. Protein expression was induced with 1 mM IPTG.
Cells were broken using the French Press and were then purified
on Ni-NTA resin (QIAGEN) followed by size-exclusion chroma-
tography using Superdex 200 (GE Healthcare) column. All
proteins were purified in their native state. Proteins were stored
in buffer A (25 mM TrisHCl, pH 7.5, 150 mM KCl, 10%
glycerol, and 0.5 mM DTT).
The untagged E. coli HtpG was expressed in E. coli BL21 (DE3)
transformed with plasmid pHB40P (a gift from Dr. David Agard).
Cells were lysed by sonication and the protein was precipitated by
(NH4)2SO4 at a final concentration of 75%. The pellet was
resuspended and applied onto Q-Sepharose (GE Healthcare). The
HtpG eluant, at about 500 mM KCl, was applied on Superdex
200 size exclusion column and then stored in buffer A.
ATPase Activity Assay
ATPase activity of Hsp90s, ClpX, and Hsp70 were measured
using the coupled LDH/NADH method as described [22]. Briefly,
the reaction mixture was set up in a final volume of 500 mL
containing 25 mM HEPES, 5 mM MgCl2,3 mM Hsp90 or
0.6 mM ClpX or 1.4 mM Hsp70 (monomer concentration), 5 mM
ATP, 0.2 mM NADH, 3 mM phosphoenolpyruvate, 15.6 U
pyruvate kinase (Sigma), 24.5 U lactate dehydrogenase (Sigma),
0.03% Tween 20, and 10% glycerol. For experiments in high salt
concentration, KCl was included in the reaction mix at a final
concentration of 400 mM, otherwise, 40 mM KCl was included.
The decrease in NADH absorbance at 340 nm was recorded
continuously for 40 minutes using a Cary 300 Bio UV-VIS
spectrophotometer (Varian).
Before starting the reaction, the mixture without the ATPase
was incubated at 37uC for 2 minutes and then NADH absorbance
was recorded for 3 minutes and used as background to account for
spontaneous ATP hydrolysis. The ATPase was then added and
ATP hydrolysis was monitored by the decrease in NADH
absorbance. Tamoxifen (Sigma), 4-hydroxytamoxifen (Sigma),
raloxifene (Sigma), or geldanamycin (National Institute of Health)
dissolved in DMSO was subsequently added to the reaction. The
purity of tamoxifen and 4-hydroxytamoxifen (4-OHT) was judged
to be .98% based on mass spectrometry analysis of the samples.
The specific activity of the ATPase was calculated as described
[22].
Surface Plasmon Resonance (SPR) measurements
SPR measurements were conducted on a BiacoreX instrument
(GE Healthcare) at 25uC. Yeast Hsp82 was immobilized to one of
two flow cells on CM5 chips (GE Healthcare) using the Biacore
amine coupling kit (GE Healthcare) following the manufacturer’s
protocols. The reference flow cell was sham activated and
deactivated without protein immobilization. Immobilizations were
performed in buffer B (10 mM HEPES, pH 7.5, 150 mM KCl,
3 mM EDTA, and 0.005% P20 surfactant). After surface
activation, 10,000–15,000 Response Units (RU) of immobilized
ligand was typically obtained with a 30 mL injection of 50 mg/mL
yeast Hsp82 or Hsp82 N-domain (Hsp82N) in 10 mM sodium
acetate, pH 4.5 over the activated flow cell.
Direct binding experiments were performed at a flow rate of
20 mL/min in buffer C (10 mM HEPES, pH 7.5, 150 mM KCl,
10 mM MgCl2, 3 mM EDTA, and 0.005% P20 surfactant).
Various concentrations of ADP, raloxifene, or 4-OHT analyte
were injected over yeast Hsp82 coupled biosensor chip surfaces.
Each 60 seconds injection of analyte was followed by 60 seconds of
running buffer flow before the chip and sample loop were washed
using high flow rate, after which, the sensorgram signal returned to
baseline. The sensorgrams in the reference surface were subtracted
from the corresponding sensorgrams in the protein-immobilized
flow cell to remove the effect of nonspecific binding to the chip
surface and the bulk effect from the buffer. Since the high
refractive index of the DMSO in the sample combined with the
high density of immobilized protein on the ligand surface resulted
in an excluded volume effect, each injection was double referenced
with a second injection of equivalent buffer composition minus
analyte. For the direct binding experiments, each injection
contained 2% DMSO. The steady state responses were plotted
Figure 1. 4-OHT Activates Hsp90 ATPase. (A) Conformation of 4-OHT (magenta) docked onto the crystal structure of the N-terminal ATP-
binding domain of human Hsp90a (yellow mesh, pdb code 1uy8). 4-OHT occupies the nucleotide binding pocket as illustrated by the superimposed
structure of human Hsp90a N-terminal domain (not shown for clarity–pdb code 1byq, backbone RMSD 1.45 A ˚) co-crystallized with ADP (white).
Unlike ADP, the 4-OHT aliphatic chain extends deep into the pocket, and makes multiple hydrophobic contacts with the lid which acts as a structural
switch between the active (green–pdb code 2cg9) and inactive (red–pdb code 1uy8) conformation of the enzyme. (B–D) The effects of 4-OHT and
raloxifene on Hsp90 ATPase activity are shown in low salt (40 mM KCl, red) and high salt (400 mM KCl, blue) buffer. All ATPase activities refer to the
ATPase inhibited by 20 mM geldanamycin (refer to Materials and Methods) and are relative to that of yeast Hsp82, which has a measured
geldanamycin-inhibited ATPase activity of 4.85 (60.19) pmol Pi min
21 mg
21. Data shown are averages of three to five repeats. Error bars refer to the
standard deviation. Stars on selected bars indicate that the average value obtained for that experiment is statistically different from the average
obtained in the absence of the drug using the Z-test at the 95% confidence limit.
doi:10.1371/journal.pone.0009934.g001
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site Langmuir binding model by nonlinear regression using the
BiaEvaluation 4.1 software (GE Healthcare).
As a variation to the above-described equilibrium binding
experiments, binding curves for ADP or ATP to chip-immobilized
yeast Hsp82 or Hsp82N were obtained in the presence of
raloxifene and 4-OHT. The running buffer used in these
experiments mimicked the high salt buffer used in the ATPase
assays, buffer D (25 mM HEPES, pH 7.5, 400 mM KCl, 5 mM
MgCl2, and 10% DMSO) with 25 mM of 4-OHT or raloxifene.
The injection phase was 120 seconds followed by 60 seconds of
buffer flow before the cells were washed at high flow rate.
Results
Effect of 4-hydroxytamoxifen (4-OHT) on Hsp90 ATPase
activity
The project initially started with the intent of identifying
unexpected targets of the anti-estrogen drug tamoxifen (TAM).
Hence, 4-hydroxytamoxifen (4-OHT),the activemetabolite of TAM,
was docked to the crystal structure of over 4000 druggable pockets
extracted from the protein data bank using a virtual screening
approach [19]. Each structure was assigned a score based on the
quality of the fit (Table S1). The top 15 scoring hits were 12 estrogen
receptor structures and 3 Hsp90 structures (pdb codes 1uyf, 1uy8,
and 2ior–see Table S1). The hits to estrogen receptors are expected
since TAM competes with estrogen for binding to estrogen receptors,
and is typically used in the treatment of advanced breast cancer in
women whose tumors are estrogen-dependent [23]. However, the
hits to Hsp90 were unexpected (Figure 1A) and suggested a novel
activity for TAM and its derivatives. It should be pointed out that,
even though 4-OHT docked well to the Hsp90 ATP pocket, no
similarity was identified between the structural chemistry of this site
and of the ligand binding pocket of the estrogen receptor using the
online server SuMo [24]. As a negative control, celebrex, another
unrelated drug, was docked to the same collection of pockets. While
cyclooxygenase 2, the known target of celebrex, was ranked number
1, the first Hsp90 structure ranked 132 with a bad score (Table S1).
The effect of 4-OHT on the ATPase activity of Hsp90 was then
measured at low salt (40 mM KCl) and high salt concentrations
(400 mM KCl) using different forms of Hsp90. Salt alone
enhanced the ATPase activity of Saccharomyces cerevisiae (yeast)
and E. coli Hsp90 by a factor of about 2 and 4, respectively
(Figure 1B, C). This is consistent with previous reports [25]. For
human Hsp90, reliable data was only obtained at high salt
concentration since this chaperone has very low ATPase activity.
To our surprise, we found that 4-OHT enhanced, rather than
inhibited, the ATPase activity of yeast, E. coli, and human Hsp90
(Figures 1B–D and Figure 2A). Such an enhancement was also
observed for TAM (data not shown).
At low salt concentration, the enhancement by 52 mM 4-OHT
was about 3 fold, while, at high salt concentration, the
enhancement was about 1.5 fold for all three forms of Hsp90
(Figure 1B–D). The ATPase activity measured was inhibited by
geldanamycin (Figure 2A,B), clearly indicating that the activity
arises from Hsp90. Another selective estrogen receptor modulator,
raloxifene, did not enhance Hsp90 ATPase activity as much as 4-
OHT (Figure 1B, C). For example, in low salt buffer, 39 mM
raloxifene enhanced Hsp90 ATPase by 1.46 (60.35) fold, while
39 mM 4-OHT enhanced the chaperone ATPase by 2.42 (60.38)
(Figure 1B). Raloxifene docked well to one of the Hsp90 structures
(pdb code 1uyf), but not to the best 2 scoring structures for
tamoxifen (pdb codes 2ior and 1uy8). This difference in docking
results between tamoxifen and raloxifene may reflect the observed
difference in their ability to activate HSP90, although it might just
be a result of the limits of docking simulations.
The enhancement of Hsp90 ATPase activity by 4-OHT
requires the full length chaperone, since no such effect was
observed when using a truncated version of yeast Hsp90
containing only the N-terminal ATP-binding domain and the
middle domain of the chaperone (Figure 1B). This construct has
about 40% of the ATPase activity of the full length chaperone in
the high salt buffer. Furthermore, 4-OHT did not affect the
ATPase activity (maybe caused a slight inhibition) of other
unrelated chaperones such as E. coli ClpX and human Hsp70
(Figure 2C,D).
Binding of 4-OHT to Hsp82
The observed enhancement of Hsp90 ATPase activity by 4-OHT
in our experiments seems to contradict the docking model (Figure 1A)
in which the drug molecule occupies the ATP-binding pocket, and
should presumably compete with ATP-binding to Hsp90. Hence, we
next attempted to experimentally demonstrate that 4-OHT binds to
the N-terminus of Hsp82 as predicted by the docking approach. To
this end, we carried out surface plasmon resonance (SPR)
experiments using the Biacore system. The binding constants
obtained for the direct binding of ATP or ADP to full length yeast
Hsp82 (Figure 3) or Hsp82N (Figure 4) immobilized on the biosensor
chip were in general agreement with those published in the literature
(refer for example to reference [10]). It is generally observed that the
binding of ATP to Hsp82 or Hsp82N is weaker than that of ADP.
Both the titrations of raloxifene and 4-OHT were problematic
(Figure 3), since the high refractive index of DMSO in the samples
gave rise to artifacts from the differences between the running buffer
and the injected sample. The titration of raloxifene yielded data
which did not reach saturation indicating unspecific binding. On the
other hand, the titration of 4-OHT, while also quite noisy, did reach
saturation, although the fits did not provide a reliable value for the
Kd.T h eK d is estimated to be between 10 and 100 mM. The same
experiments were done using chip-immobilized yeast Hsp82N with
similar results (data not shown). Binding experiments were also
attempted using isothermal titration calorimetry, however, again we
encountered problems with low signal and high noise.
In another approach to demonstrate that 4-OHT can directly
compete with nucleotides for binding to Hsp82N, the SPR
experiments were repeated but raloxifene or 4-OHT was included
in the running buffer at 25 mM .A ss h o w ni nF i g u r e4 ,r a l o x i f e n ed i d
not compete appreciably with ATP or ADP binding to Hsp82N.
However,when4-OHT was included with the running buffer, no net
binding responsewas observed up to 200 mM ATP (Figure4).Onthe
other hand, the binding of ADP to Hsp82N was not significantly
Figure 2. Control Experiments for the Effect of 4-OHT on Hsp90 ATPase. (A) Raw ATPase data showing the effect of 4-OHT on yeast Hsp82
as monitored by the decrease in NADH absorbance. (B) Effect of geldanamycin on human Hsp90a ATPase activity in the presence of 52 mM 4-OHT in
high salt buffer. (C) Effect of 4-OHT on the ATPase activity of E. coli ClpX in low salt buffer. (D) Effect of 4-OHT on the ATPase activity of human Hsp70
in low salt buffer. All ATPase activities given refer to total activity and not to the geldanamycin-inhibited ATPase. They are given relative to the
geldanamycin-inhibited ATPase activity of yeast Hsp82 [4.85 (60.19) pmol Pi min
21 mg
21]. Data shown are averages of three to five repeats. Error bars
refer to the standard deviation. Stars on selected bars indicate that the average value obtained for that experiment is statistically different from the
average obtained in the absence of the drug using the Z-test at the 95% confidence limit.
doi:10.1371/journal.pone.0009934.g002
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suggest that the binding of 4-OHT to Hsp90 is stronger than ATP
but weaker than ADP. Hence, we estimate the Kd for binding of 4-
OHT to Hsp82 to be of the order of 60–100 mM.
Discussion
The observation that 4-OHT activates rather than inhibits
Hsp90 ATPase, even though it was initially docked onto the N-
terminal ATP-binding pocket of the chaperone (Figure 1A) is an
unexpected finding. The SPR experiments of Figures 3 and 4 seem
to suggest that 25 mM 4-OHT can compete with up to 200 mM
ATP for binding to Hsp82 N-domain, but not with ADP. The
results do not formally exclude the possibility that 4-OHT might
bind at a site in Hsp82N different from that of the ATP pocket,
which would cause an allosteric inhibition for the binding of ATP
in the nucleotide pocket.
The ATPase assays were carried out using 4-OHT concentra-
tions up to 52 mM and ATP concentration of 5 mM (Figures 1 and
2), while Hsp90 concentration is 3 mM (see Materials and
Methods). Since the Kd of 4-OHT and nucleotide binding to
Hsp90 are all in the mM range, (Figure 3 and 4), then, under the
ATPase assay condition, we expect nucleotide to be preferentially
bound by Hsp90 by a factor of approximately 1000 to 1 over 4-
OHT. To reconcile the observation that 4-OHT binds at or near
the ATP pocket but at the same time enhances the ATPase activity
Figure 3. SPR Measurements for ATP, ADP, Raloxifene, and 4-OHT Binding to Yeast Hsp82 Immobilized on Biosensor Chip. Various
concentrations of ATP, ADP, raloxifene, and 4-OHT were injected over a surface immobilized with yeast Hsp82. The sensorgrams shown have been
double referenced. The steady state responses were fit, where possible, using nonlinear regression to a single class of binding site model to obtain
the Kd values indicated. Numbers in parenthesis give the standard errors on the Kd obtained from the fits.
doi:10.1371/journal.pone.0009934.g003
Tamoxifen Activates Hsp90
PLoS ONE | www.plosone.org 6 April 2010 | Volume 5 | Issue 4 | e9934of Hsp90 when present at 1000 fold lower concentrations than that
of ATP, we propose that, 4-OHT might affect the kinetics of ATP
hydrolysis and ADP or Pi release. This seems to be suggested by
the results of the experiments of Figure 4. The validation of this
proposal will require detailed kinetic, mutational, and structural
analyses of drug binding to Hsp90. For example, based on the
observations made, we expect that increasing the concentration of
4-OHT to mM concentrations in the ATPase assay should
eventually inhibit the ATPase activity of Hsp90. Unfortunately, 4-
OHT is not an ideal drug for such studies due to its limited
solubility and tendency to precipitate at concentrations above
52 mM used in our assays (Figures 1 and 2).
To our knowledge, 4-OHT is the first small molecule of a new
pharmacological class of Hsp90 activators. Although this off-
target effect of 4-OHT on Hsp90 is only observed at micromolar
drug concentrations, it is probable that 4-OHT can be chemically
modified to become a more potent activator of Hsp90. The
structural mechanism of pharmacological activation of Hsp90
and its potential translational applications deserve further
investigation.
Supporting Information
Table S1 The ICM docking score of 4-hydroxy tamoxifen and
celebrex against all 4403 pockets extracted from the PDB are
shown. The lowest scores are the best. ICM user’s manual
recommends to discard docking results scoring higher than -32.
Found at: doi:10.1371/journal.pone.0009934.s001 (1.44 MB
XLS)
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